187 related articles for article (PubMed ID: 25302696)
21. Evaluating the Role of the Air-Solution Interface on the Mechanism of Subvisible Particle Formation Caused by Mechanical Agitation for an IgG1 mAb.
Ghazvini S; Kalonia C; Volkin DB; Dhar P
J Pharm Sci; 2016 May; 105(5):1643-1656. PubMed ID: 27025981
[TBL] [Abstract][Full Text] [Related]
22. Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation.
Randolph TW; Schiltz E; Sederstrom D; Steinmann D; Mozziconacci O; Schöneich C; Freund E; Ricci MS; Carpenter JF; Lengsfeld CS
J Pharm Sci; 2015 Feb; 104(2):602-11. PubMed ID: 25418950
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of Stress-Induced Aggregate Size Distributions and Morphological Changes of a Bi-Specific Antibody Using Orthogonal Techniques.
Hamrang Z; Hussain M; Tingey K; Tracka M; Casas-Finet JR; Uddin S; van der Walle CF; Pluen A
J Pharm Sci; 2015 Aug; 104(8):2473-81. PubMed ID: 26053418
[TBL] [Abstract][Full Text] [Related]
24. Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis.
Zhang K; Wrzosek T; Desai KG; Monck M
PDA J Pharm Sci Technol; 2020; 74(1):15-26. PubMed ID: 31519785
[TBL] [Abstract][Full Text] [Related]
25. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
[TBL] [Abstract][Full Text] [Related]
26. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis.
Zölls S; Gregoritza M; Tantipolphan R; Wiggenhorn M; Winter G; Friess W; Hawe A
J Pharm Sci; 2013 May; 102(5):1434-46. PubMed ID: 23463514
[TBL] [Abstract][Full Text] [Related]
27. Unmasking translucent protein particles by improved micro-flow imaging™ algorithms.
Pedersen JS; Persson M
J Pharm Sci; 2014 Jan; 103(1):107-14. PubMed ID: 24281987
[TBL] [Abstract][Full Text] [Related]
28. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
Sharma DK; Oma P; Pollo MJ; Sukumar M
J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
[TBL] [Abstract][Full Text] [Related]
29. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
[TBL] [Abstract][Full Text] [Related]
30. Measurement of Average Aggregate Density by Sedimentation and Brownian Motion Analysis.
Cavicchi RE; King J; Ripple DC
J Pharm Sci; 2018 May; 107(5):1304-1312. PubMed ID: 29409841
[TBL] [Abstract][Full Text] [Related]
31. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.
Telikepalli SN; Kumru OS; Kalonia C; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
J Pharm Sci; 2014 Mar; 103(3):796-809. PubMed ID: 24452866
[TBL] [Abstract][Full Text] [Related]
32. Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations.
Akhunzada ZS; Hubert M; Sahin E; Pratt J
Curr Pharm Biotechnol; 2019; 20(3):232-244. PubMed ID: 30767738
[TBL] [Abstract][Full Text] [Related]
33. Gelation of a monoclonal antibody at the silicone oil-water interface and subsequent rupture of the interfacial gel results in aggregation and particle formation.
Mehta SB; Lewus R; Bee JS; Randolph TW; Carpenter JF
J Pharm Sci; 2015 Apr; 104(4):1282-90. PubMed ID: 25639229
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of aggregate and silicone-oil counts in pre-filled siliconized syringes: An orthogonal study characterising the entire subvisible size range.
Shah M; Rattray Z; Day K; Uddin S; Curtis R; van der Walle CF; Pluen A
Int J Pharm; 2017 Mar; 519(1-2):58-66. PubMed ID: 28089934
[TBL] [Abstract][Full Text] [Related]
35. Quantitative laser diffraction method for the assessment of protein subvisible particles.
Totoki S; Yamamoto G; Tsumoto K; Uchiyama S; Fukui K
J Pharm Sci; 2015 Feb; 104(2):618-26. PubMed ID: 25449441
[TBL] [Abstract][Full Text] [Related]
36. Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.
Krause N; Kuhn S; Frotscher E; Nikels F; Hawe A; Garidel P; Menzen T
AAPS J; 2021 Jan; 23(1):13. PubMed ID: 33398482
[TBL] [Abstract][Full Text] [Related]
37. Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance.
Boll B; Bessa J; Folzer E; Ríos Quiroz A; Schmidt R; Bulau P; Finkler C; Mahler HC; Huwyler J; Iglesias A; Koulov AV
Mol Pharm; 2017 Apr; 14(4):1292-1299. PubMed ID: 28206769
[TBL] [Abstract][Full Text] [Related]
38. Colloidal Instability Fosters Agglomeration of Subvisible Particles Created by Rupture of Gels of a Monoclonal Antibody Formed at Silicone Oil-Water Interfaces.
Mehta SB; Carpenter JF; Randolph TW
J Pharm Sci; 2016 Aug; 105(8):2338-48. PubMed ID: 27422087
[TBL] [Abstract][Full Text] [Related]
39. Agitation-induced aggregation and subvisible particulate formation in model proteins.
Jayaraman M; Buck PM; Ignatius AA; King KR; Wang W
Eur J Pharm Biopharm; 2014 Jul; 87(2):299-309. PubMed ID: 24462794
[TBL] [Abstract][Full Text] [Related]
40. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
